Cellular Responses to Cisplatin-Induced DNA Damage

被引:385
作者
Basu, Alakananda [1 ]
Krishnamurthy, Soumya
机构
[1] Univ North Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA
关键词
D O I
10.4061/2010/201367
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cisplatin is one of the most effective anticancer agents widely used in the treatment of solid tumors. It is generally considered as a cytotoxic drug which kills cancer cells by damaging DNA and inhibiting DNA synthesis. How cells respond to cisplatin-induced DNA damage plays a critical role in deciding cisplatin sensitivity. Cisplatin-induced DNA damage activates various signaling pathways to prevent or promote cell death. This paper summarizes our current understandings regarding the mechanisms by which cisplatin induces cell death and the bases of cisplatin resistance. We have discussed various steps, including the entry of cisplatin inside cells, DNA repair, drug detoxification, DNA damage response, and regulation of cisplatin-induced apoptosis by protein kinases. An understanding of how various signaling pathways regulate cisplatin-induced cell death should aid in the development of more effective therapeutic strategies for the treatment of cancer.
引用
收藏
页数:16
相关论文
共 226 条
[1]   Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein [J].
Abedini, M. R. ;
Muller, E. J. ;
Bergeron, R. ;
Gray, D. A. ;
Tsang, B. K. .
ONCOGENE, 2010, 29 (01) :11-25
[2]   Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells [J].
Abedini, Mohammad R. ;
Muller, Emilie J. ;
Brun, Jan ;
Bergeron, Richard ;
Gray, Douglas A. ;
Tsang, Benjamin K. .
CANCER RESEARCH, 2008, 68 (12) :4511-4517
[3]  
Aebi S, 1996, CANCER RES, V56, P3087
[4]   Bypass of DNA lesions generated during anticancer treatment with cisplatin by DNA polymerase [J].
Alt, Aaron ;
Lammens, Katja ;
Chiocchini, Claudia ;
Lammens, Alfred ;
Pieck, J. Carsten ;
Kuch, David ;
Hopfner, Karl-Peter ;
Carell, Thomas .
SCIENCE, 2007, 318 (5852) :967-970
[5]   Pharmacological inhibitors of extracellular signal-regulated protein kinases attenuate the apoptotic action of cisplatin in human myeloid leukemia cells via glutathione-independent reduction in intracellular drug accumulation [J].
Amrán, D ;
Sancho, P ;
Fernández, C ;
Esteban, D ;
Ramos, AM ;
de Blas, E ;
Gómez, M ;
Palacios, MA ;
Aller, P .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2005, 1743 (03) :269-279
[6]  
ANDREWS PA, 1991, CANCER RES, V51, P3677
[7]  
ANDREWS PA, 1987, CANCER CHEMOTH PHARM, V19, P149
[8]   Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells [J].
Arora, Sanjeevani ;
Kothandapani, Anbarasi ;
Tillison, Kristin ;
Kalman-Maltese, Vivian ;
Patrick, Steve M. .
DNA REPAIR, 2010, 9 (07) :745-753
[9]  
Asselin E, 2001, CANCER RES, V61, P1862
[10]   Distinct effects of the recurrent Mlh1G67R mutation on MMR functions, cancer, and meiosis [J].
Avdievich, Elena ;
Reiss, Cora ;
Scherer, Stefan J. ;
Zhang, Yongwei ;
Maier, Sandra M. ;
Jin, Bo ;
Hou, Harry, Jr. ;
Rosenwald, Andreas ;
Riedmiller, Hubertus ;
Kucherlapati, Raju ;
Cohen, Paula E. ;
Edelmann, Winfried ;
Kneitz, Burkhard .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (11) :4247-4252